-+ 0.00%
-+ 0.00%
-+ 0.00%

Trevi Therapeutics plans two Phase 3 trials of nalbuphine ER for IPF-related chronic cough after FDA meeting

Reuters·03/09/2026 11:31:00

Please log in to view news